Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (133,725)	$ (151,059)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	16,260	25,061
Depreciation and amortization expense	9,142	14,605
Loss on securities purchase agreement put/call	4,029	0
Net amortization and accretion on marketable securities	(3,899)	(11,716)
Loss on property and equipment disposals, net	3,510	417
Non-cash lease income	(2,511)	(1,591)
Change in fair value of contingent consideration payable	(1,706)	0
Impairment of long-lived assets	1,443	0
Change in fair value of success payment liabilities	221	(669)
Loss (gain) on marketable equity security	29	(47)
Impairment of other investments	0	13,001
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	5,216	(1,861)
Accounts payable	(2,664)	(1,198)
Accrued liabilities and other current liabilities	(12,546)	4
Other non-current liabilities	(572)	(99)
Net cash used in operating activities	(117,773)	(115,152)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(476)	(420)
Sales of property and equipment	263	0
Purchases of marketable securities	(236,099)	(355,905)
Maturities of marketable securities	321,774	425,244
Net cash provided by investing activities	85,462	68,919
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from securities purchase agreement equity issuance	50,000	0
Proceeds from exercise of stock options	0	155
Proceeds from employee stock purchase plan	184	810
Taxes paid related to net share settlement of equity awards	0	(76)
Net cash provided by financing activities	50,184	889
Net increase (decrease) in cash, cash equivalents and restricted cash	17,873	(45,344)
Cash, cash equivalents and restricted cash at beginning of period	107,287	145,931
Cash, cash equivalents and restricted cash at end of period	125,160	100,587
Represented by:
Cash and cash equivalents	123,575	100,299
Restricted cash	1,585	288
Total	125,160	100,587
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for amounts included in the measurement of lease liabilities	9,419	8,449
Non-cash investing and financing activities:
Securities purchase agreement put/call issuance	7,774	0
Equity issued for contingent consideration — ImmPACT Bio USA Inc. acquisition	5,894	0
Purchases of property and equipment included in accounts payable and accrued liabilities	$ 0	$ 23